The Perioperative Use of Levosimendan as a Means of Optimizing the Surgical Outcome in Patients with Severe Heart Insufficiency Undergoing Cardiac Surgery.

Leivaditis, Vasileios; Grapatsas, Konstantinos; Papaporfyriou, Anastasia; Galanis, Michail; Koletsis, Efstratios; Charokopos, Nikolaos; Haussmann, Erich; Kaplunov, Vladislav; Papatriantafyllou, Athanasios; Dahm, Manfred (2023). The Perioperative Use of Levosimendan as a Means of Optimizing the Surgical Outcome in Patients with Severe Heart Insufficiency Undergoing Cardiac Surgery. Journal of cardiovascular development and disease, 10(8) MDPI 10.3390/jcdd10080332

[img]
Preview
Text
jcdd-10-00332.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (2MB) | Preview

BACKGROUND

Postoperative myocardial dysfunction following cardiac surgery is a relatively common occurrence. Levosimendan, a calcium sensitizer and inotropic drug, has shown potential in improving outcomes for patients with low preoperative ejection fraction (EF) and myocardial dysfunction after cardiac surgery. This study aims to evaluate the efficacy of levosimendan in optimizing the surgical outcome for such patients.

METHODS

A retrospective analysis was conducted on 314 patients with preoperative severe heart failure who underwent cardiac surgery. Among them, 184 patients received perioperative adjunctive therapy with levosimendan, while a comparable group of 130 patients received conventional treatment.

RESULTS

The use of levosimendan demonstrated several advantages in postoperative outcomes. It significantly improved short- and long-term survival rates after cardiac surgery, enhanced hemodynamic stability, reduced the requirement for inotropic support, and facilitated faster weaning from ventilator support. Patients who received levosimendan reported reduced angina and dyspnea symptoms, as well as fewer postoperative arrhythmias. Furthermore, levosimendan helped minimize myocardial injury inevitable after cardiac surgery. The levosimendan group also exhibited a notable reduction in hospital readmissions.

CONCLUSIONS

This study provides evidence of several benefits associated with the perioperative use of levosimendan. However, further prospective randomized studies are warranted to standardize and comprehensively document the other perioperative therapies, in order to validate these findings and establish stronger conclusions.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Thoracic Surgery

UniBE Contributor:

Galanis, Michail

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2308-3425

Publisher:

MDPI

Language:

English

Submitter:

Pubmed Import

Date Deposited:

30 Aug 2023 10:50

Last Modified:

23 Nov 2023 15:43

Publisher DOI:

10.3390/jcdd10080332

PubMed ID:

37623345

Uncontrolled Keywords:

angina pectoris cardiac surgery heart failure levosimendan myocardial injury

BORIS DOI:

10.48350/185760

URI:

https://boris.unibe.ch/id/eprint/185760

Actions (login required)

Edit item Edit item
Provide Feedback